TGFB1 and non-small cell lung carcinoma: Interestingly, a recent clinical study of a related genistein-based oral drug formulation, BIO 300 Oral Suspension, in patients with non-small cell lung cancer undergoing chemoradiotherapy demonstrated that patients had a BIO 300 Oral Suspension dose-dependent decrease in serum TGF-β levels [37].